Portfolio: Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), ALS-Frontotemporal Degeneration (ALS-FTD)
Additional Keywords: Accelerating Medicines Partnership for Amyotrophic Lateral Sclerosis (AMP-ALS); SOD1, FUS, TDP-43, C9orf72, TBK1; skeletal muscle; motor neuron; axon degeneration and autophagy; motor neuron death
Dr. Amelie Gubitz serves as a Program Director for Amyotrophic Lateral Sclerosis (ALS) in the Division of Neuroscience at the National Institute of Neurological Disorders and Stroke. She also supports the Accelerating Medicines Partnership® for ALS (AMP® ALS). Dr. Gubitz earned a Ph.D. in pharmacology from the University of Cambridge, UK, and then completed a Wellcome Trust Fellowship at Harvard Medical School in circadian biology. She has also worked as a Senior Scientist in the target discovery group for neuropathic pain at Parke Davis, UK, and as a Research Assistant Professor at the University of Pennsylvania where she studied the molecular pathogenesis of spinal muscular atrophy.